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Although biological therapy has shown promising clinical responses in many
cancers including metastatic melanoma, only a subset of patients has
shown marked regression of lesions. In most patients, systemic administration
of biological therapies with cytokines is associated with severe toxicities.
Schwager et al., in this issue of Journal of Investigative Dermatology, have
examined the role of immunocytokines L19-IL2 and L19-TNF to minimize
toxicities, and in combination with Ipilimumab they report complete regression
of tumors using syngeneic mouse models. The results, if confirmed in clinical
trials, will have major implications for the treatment of human cancers, including
melanomas.
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Metastatic melanoma is an aggressive
form of skin cancer with limited treat-
ment options. Melanoma patients are
resistant to conventional chemotherapy
(dacarbazine and temozolomide), and
they also develop resistance to a
recently approved targeted therapy drug
Vemurafenib. Vemurafenib has shown
marked reduction of tumor burden with
near doubling of the overall survival
of melanoma patients to B16 months
(Flaherty and Fisher, 2011). Clinical
trials are underway to improve overall
survival of melanoma patients,
further using combination therapy of
Vemurafenib and Ipilimumab. Ipili-
mumab (also known as Yervoy) is a
human monoclonal antibody directed
against cytotoxic T-lymphocyte antigen
4 (CTLA4), an immune checkpoint
molecule on the surface of activated T
cells. Treatment of patients with
Ipilimumab alone prolongs survival of
B20% of patients, leading to renewed
interest in immunological therapies of
melanoma (Mellman et al., 2011). In the
past, biological therapies in melanoma
patients with cytokines such as IL2 or
IFN-a showed transient responses but
little benefit in overall survival. In a
small subset of melanoma patients,
however, high-dose IL2, which
enhances both T-cell– and natural
killer (NK) cell–mediated antitumor
activities, can induce significant
responses. Locally administered high-
dose tumor necrosis factor-a (TNF-a) in
combination with melphalan is very
effective in reducing tumor burden
(Grunhagen et al., 2004). However, in
most patients, cytokine therapies are
invariably accompanied by severe
toxicities (Mellman et al., 2011).
To overcome the toxicities of systemic
administration of cytokines, several stu-
dies have used targeted delivery of
cytokines, either alone or in combina-
tion with chemotherapy, with encoura-
ging results (Dehal et al., 2002; Fan
et al., 2010; Moschetta et al., 2012).
TNF (scFv) of an antibody fused with a
cytokine (immunocytokine) has also
See related article on pg 751 been used successfully to reduce
toxicities effectively and to improve the
survival of cancer patients (Johannsen
et al., 2010; Eigentler et al., 2011). An
antibody (L19) directed against the
unique ED-B domain of fibronectin, a
matrix protein expressed in tumor blood
vessels, has been used in the clinics for
radioimaging and radioimmunotherapy
(Tijink et al., 2006; Rossin et al., 2007;
Tijink et al., 2009). The scFv of the L19
antibody was fused with the cytokines
IL2 or TNF-a for targeted delivery to the
tumor. These immunocytokines, when
tested in several phase I/II clinical trials,
showed beneficial effects and minimal
toxicity for a wide range of tumor
types, including metastatic melanoma
(Eigentler et al., 2011). In several
animal tumor models, immunocytokine
L19-IL2 showed potent antitumor
activity by activating several types of
immune cells, including macrophages,
NK cells, and CD4þ and CD8þ T
cells (Halin et al., 2002; Wagner et al.,
2008; Schliemann et al., 2009). In a
small cohort of patients with
unresectable melanoma lesions in the
limbs, local administration of L19-TNF
plus melphalan with mild hyper-
thermia induced objective responses
(Papadia et al., 2012). Collectively,
immunocytokines showed potent
antitumor activities and less toxicity
compared with systemic administration
of cytokines.
In this issue of Journal of Investigative
Dermatology, Schwager et al. (2012)
have used immunocytokines to specifi-
cally deliver IL2 or TNF-a to tumor sites.
In the mouse F9 teratocarcinoma model,
anti-CTLA4 antibodies alone had no
effect on tumor growth, as these cells
lack major histocompatibility complex-
class I molecules, and hence lack
T-cell–mediated tumor inhibition.
However, L19–IL2 fusion protein treat-
ment led to significant tumor growth
delay due to IL2 activation of NK cells,
but not complete regression owing to
the lack of T-cell activity. Combining
L19–IL2 with anti-CTLA4 antibody also
resulted in significant tumor growth
delay compared with either treatment
alone. Complete tumor regression was
seen in a small number of mice. Similar
results were seen with the combination
therapy of L19–IL2 and anti-CTLA4 in
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the CT-26 colon carcinoma model.
Antitumor immunity in this model was
due mainly to T cells, but not due to NK
cells. Interestingly, when mice with
complete tumor regression were rechal-
lenged with CT-26 tumor cells, no
tumor growth was observed, indicating
a protective T-cell memory response
against CT-26 cells. Tumors were infil-
trated by T cells, NK cells, B cells, and
macrophages. Surprisingly, combination
therapy of L19–IL2 with anti-PD-1 anti-
body, a more potent immune check-
point reagent similar to anti-CTLA4
antibody, resulted in delayed tumor
growth but not complete tumor regres-
sion. Finally, combining immunocyto-
kine L19–IL2 and L19–TNF locally in
the F9 teratocarcinoma resulted in
strong synergistic antitumor activities
leading to complete regression.
Combination therapies
using immunocytokines
and Ipilimumab are on
the horizon for clinical
trials.
On the basis of the above observa-
tions and the promising therapeutic
activity of L19–IL2 in early clinical
trials, Schwager et al. (2012) have
suggested two therapeutic options for
the treatment of metastatic melanoma.
The first is to combine L19–IL2 with
Ipilimumab, and the second is to com-
bine L19–IL2 with L19–TNF to
eradicate superficial lesions of late-stage
melanoma.
Although there is a potential benefit
of combining L19–IL2 with anti-CTLA4
or L19–IL2 with L19–TNF, further
studies need to be conducted in patients
to confirm these findings. Only a sub-
group of melanoma patients treated with
Ipilimimab show prolonged survival.
In this group, patients with increased
number of tumor-infiltrating lympho-
cytes after treatment with Ipilimumab
benefited the most. Similar beneficial
responses of increased lymphocyte infil-
tration after combined treatment with
L19–IL2 and Ipilimumab were also
observed in Schwager’s mouse tumor
models. However, it is unclear whether
the increased lymphocyte infiltration
caused direct regression of tumors. An
in-depth analysis of the mechanism of
tumor regression after treatment of Ipili-
mumab and L19–IL2 would provide a
foundation for future trials. In Schwa-
ger’s study, Schwager et al. (2013) the
administration of immunocytokine L19–
IL2 did not increase the number of
regulatory T cells (Tregs). This may be
because of low baseline levels of Tregs
in the mouse models. In some cancer
patients, higher baseline levels of Tregs
may lead to further enhancement and
functional activation of regulatory cells
due to the presence of L19–IL2 in the
tumor microenvironment, resulting in
dampening of the overall immune
response. The presence of Ipilimumab
should not reverse the overwhelming
functional activation due to IL2. This
may lead to inhibition of antitumor
responses. Such events need to be taken
into consideration before combina-
tion therapies using immunocytokines
and Ipilimumab are adapted to clinical
trials.
CONFLICT OF INTEREST
The authors state no conflict of interest.
REFERENCES
Dehal PK, Embleton MJ, Kemshead JT et al. (2002)
Targeted cytokine delivery to neuroblastoma.
Biochem Soc Trans 30:518–20
Eigentler TK, Weide B, de Braud F et al. (2011) A
dose-escalation and signal-generating study of
the immunocytokine L19-IL2 in combination
with dacarbazine for the therapy of patients
with metastatic melanoma. Clin Cancer Res
17:7732–42
Fan D, Yin Z, Cheong R et al. (2010) Subcellular-
resolution delivery of a cytokine through
precisely manipulated nanowires. Nat Nano-
technol 5:545–51
Flaherty KT, Fisher DE (2011) New strategies
in metastatic melanoma: oncogene-defined
taxonomy leads to therapeutic advances. Clin
Cancer Res 17:4922–8
Grunhagen DJ, Brunstein F, Graveland WJ et al.
(2004) One hundred consecutive isolated
limb perfusions with TNF-alpha and
melphalan in melanoma patients with
multiple in-transit metastases. Ann Surg
240:939–47
Halin C, Rondini S, Nilsson F et al. (2002)
Enhancement of the antitumor activity of
interleukin-12 by targeted delivery to neo-
vasculature. Nat Biotechnol 20:264–9
Johannsen M, Spitaleri G, Curigliano G et al.
(2010) The tumour-targeting human L19-IL2
immunocytokine: preclinical safety studies,
phase I clinical trial in patients with solid
tumours and expansion into patients with
advanced renal cell carcinoma. Eur J Cancer
46:2926–35
Mellman I, Coukos G, Dranoff G (2011) Cancer
immunotherapy comes of age. Nature
480:480–9
Moschetta M, Pretto F, Berndt A et al. (2012)
Paclitaxel enhances therapeutic efficacy of
the F8-IL2 immunocytokine to EDA-fibronec-
tin-positive metastatic human melanoma
xenografts. Cancer Res 72:1814–24
Papadia F, Basso V, Patuzzo R et al. (2012)
Isolated limb perfusion with the tumor-
targeting human monoclonal antibody-
cytokine fusion protein L19-TNF plus melpha-
lan and mild hyperthermia in patients
with locally advanced extremity melanoma.
J Surg Oncol; e-pub ahead of print 4 June
2012
Rossin R, Berndorff D, Friebe M et al. (2007) Small-
animal PET of tumor angiogenesis using a
(76)Br-labeled human recombinant antibody
fragment to the ED-B domain of fibronectin.
J Nucl Med 48:1172–9
Schliemann C, Palumbo A, Zuberbuhler K et al.
(2009) Complete eradication of human B-cell
lymphoma xenografts using rituximab in com-
bination with the immunocytokine L19-IL2.
Blood 113:2275–83
Schwager K, Hemmerle T, Aebischer D et al.
(2013) The immunocytokine L19-IL2 eradi-
cates cancer when used in combination with
CTLA-4 blockade or with L19-TNF. J Invest
Dermatol 133:751–8
Tijink BM, Neri D, Leemans CR et al. (2006)
Radioimmunotherapy of head and neck can-
cer xenografts using 131I-labeled antibody
L19-SIP for selective targeting of tumor vascu-
lature. J Nucl Med 47:1127–35
Tijink BM, Perk LR, Budde M et al. (2009) (124)I-
L19-SIP for immuno-PET imaging of tumour
vasculature and guidance of (131)I-L19-SIP
radioimmunotherapy. Eur J Nucl Med Mol
Imaging 36:1235–44
Wagner K, Schulz P, Scholz A et al. (2008) The
targeted immunocytokine L19-IL2 efficiently
inhibits the growth of orthotopic pancreatic
cancer. Clin Cancer Res 14:4951–60
COMMENTARY
596 Journal of Investigative Dermatology (2013), Volume 133
